Cubist Pharmaceuticals Inc $67.81

down -0.11


11/7/2014 04:25 PM  |  NASDAQ : CBST  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get CBST Trend Analysis - it has outperformed the S&P 500 by 8%

Partner Headlines

  1. Jefferies Raises Price Target On Cubist Pharmaceuticals

    Benzinga
  2. Benzinga's Top #PreMarket Gainers

    Benzinga
  3. Cubist Readies For Takeoff With New Antibiotic Launch

    IBD
  4. Cubist Pharma Reports Publicant of Pivotal Data from SIVEXTRO ESTABLISH-2 ...

    Benzinga
  5. Morning Market Movers

    Benzinga
  6. Benzinga's Top #PreMarket Gainers

    Benzinga
  7. Forest Laboratories Is an Option for Wealthy Investors Who Could Afford ...

    GuruFocus
  8. Credit Suisse Maintains on Cubist Pharmaceuticals

    Benzinga
  9. Cubist Submits CTA to Dutch Competent Authority and Ethics Committee to ...

    Benzinga
  10. Cubist Announces FDA Acceptance of Tedizolid New Drug Application with ...

    Benzinga
  11. Cubist Announces FDA Accepts Tedizolid NDA with Priority Review

    Benzinga
  12. Cubist drug passes 2nd test

    IBD
  13. Cubist Antibiotic Passes Second Test; FDA Filing Next

    IBD
  14. Stock Futures Sharply Higher; AerCap Surges On Acquisition

    IBD
  15. Cubist antibiotic passes test

    IBD
  16. Cubist Antibiotic Shines In Trials; Stock Jumps

    IBD
  17. Michael Price's Top Sells - 11 Gurus Exit SFD

    GuruFocus
  18. Top 4 NASDAQ Stocks In The Drug Manufacturers-Other Industry With The Highest ...

    Benzinga
  19. UPDATE: Wedbush Downgrades Cubist Pharmaceuticals Following Slight Q3:13 ...

    Benzinga
  20. Stocks Open Down In Firm Trade; Cree Crumbles On Q3 Results

    IBD
  21. Cubist Pharma Announces Submission of NDA for Tedizolid for Treatment of ...

    Benzinga
  22. Cubist Announces FDA Approval for Expanded Use of ENTEREG

    Benzinga
  23. UPDATE: Oppenheimer Initiates Coverage on Cubist Pharmaceuticals on Strong ...

    Benzinga
  24. UPDATE: Mizuho Securities Upgrades Cubist Pharmaceuticals on Pending Acquisitions ...

    Benzinga
  25. Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The ...

    Benzinga
  26. UPDATE: Leerink Swann Upgrades Cubist Pharmaceuticals Following Acquisition ...

    Benzinga
  27. Benzinga's Top Upgrades

    Benzinga
  28. Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The ...

    Benzinga
  29. HSR Waiting Period Expires for Cubist, Optimer Deal

    Benzinga
  30. Cubist Pharmaceuticals Issues $800M of Convertible Senior Notes

    Benzinga
  31. Cubist Pharma Reports Pricing of $700M in Convertible Senior Notes, Expecting ...

    Benzinga
  32. UPDATE: Aegis Capital Upgrades Cubist Pharmaceuticals Following Trius/Optimer ...

    Benzinga
  33. Benzinga's Top Upgrades

    Benzinga
  34. Mid-Afternoon Market Update: Fed Leaves Rates Unchanged; Green Dot Rises

    Benzinga
  35. UPDATE: Cantor Fitzgerald Raises PT on Cubist Pharmaceuticals

    Benzinga
  36. Mid-Day Market Update: Questcor Shares Jump On Upbeat Earnings, Riverbed ...

    Benzinga
  37. Mid-Morning Market Update: Markets Open Higher, MasterCard Profit Tops ...

    Benzinga
  38. UPDATE: Goldman Sachs Downgrades Cubist Pharmaceuticals Following Removal ...

    Benzinga
  39. Benzinga's Top Pre-Market Losers

    Benzinga
  40. Benzinga's Top Pre-Market Gainers

    Benzinga
  41. Benzinga's Top Upgrades

    Benzinga
  42. Benzinga Market Primer: Wednesday, July 31: Futures Higher Heading Into ...

    Benzinga
  43. Cubist Announces Acquisitions of Trius Therapeutics and Optimer Pharmaceuticals ...

    Benzinga
  44. Benzinga's M&A Chatter for Tuesday July 30, 2013

    Benzinga
  45. Cubist Pharmaceuticals to Acquire Optimer Pharmaceuticals For $10.75 In ...

    Benzinga
  46. Cubist Pharmaceuticals to Acquire Trius Therapeutics for $13.50 per Share; ...

    Benzinga
  47. Cubist Pharmaceuticals to Acquire Trius Therapeutics For $13.50 Per Share

    Benzinga
  48. Magic Formula Formulator Joel Greenblatt's Top 5 New Stock Picks

    GuruFocus
  49. UPDATE: Aegis Capital Initiates Coverage on Cubist Pharmaceuticals with ...

    Benzinga
  50. Cubist Pharmaceuticals, Inc. (CBST) President & CEO Michael W Bonney sells ...

    GuruFocus
Trading Center